LaCivita C, Funkhouser E, Miller MJ, Ray MN, Saag KG, Kiefe CI,
10.1093/ecco-jcc/jjy052 169
The authors emphasize that the potential risk of NAION with GLP-1 RA therapy warrants further investigation, particularly given the growing use of these agents and the significant impact of NAION on vision
The first major step in MDL 3094 is the request for and production of millions of pages of documents by Mounjaro manufacturer Eli Lilly
Illmer P, Erlebach C
- Klarity Health, accessed April 23, 2025, Concerns Surrounding Compounded GLP-1s Mount As Shortages of Tirzepatide, Semaglutide End - Pharmacy Times, accessed April 23, 2025, Makers of Wegovy & Zepbound Cut Prices for Those Without Insurance - HealthDay, accessed April 23, 2025, Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, accessed April 23, 2025, Continuing Semaglutide Leads to Further Weight Loss - NEJM Journal Watch, accessed April 23, 2025, Zepbound vs Wegovy for Weight Loss - Connecticut Facial Plastic Surgery, accessed April 23, 2025, Fills for Weight-Loss Medications Like Wegovy and Mounjaro Rise Despite High Out-of-Pocket Costs - GoodRx, accessed April 23, 2025,
